Mayo Clinic laboratory and pathology research roundup: June 1

By Samantha Rossi • June 1, 2021

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Therapeutic trials in adult FSGS: Lessons learned and the road forward.

Focal segmental glomerulosclerosis (FSGS) is not a specific disease entity but a lesion that primarily targets the podocyte. In a broad sense, the causes of the lesion can be divided into those triggered by a presumed circulating permeability factor, those that occur secondary to a process that might originate outside the kidneys, those caused by a genetic mutation in a podocyte or glomerular basement membrane protein, and those that arise through an as yet unidentifiable process, seemingly unrelated to a circulating permeability factor. Via Nature Reviews. Nephrology

Read more.

Published to PubMed This Week

• P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.
  Alzheimers Dementia
• Leucine zipper 4 autoantibody: A novel germ cell tumor and paraneoplastic biomarker.
  Annals of Neurology
• Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
  Neuro-Oncology
• The clinical impact of proteomics in amyloid typing.
  Mayo Clinic Proceedings
• Angiosarcoma of the adrenal gland.
  Mayo Clinic Proceedings
• Activity of biodegradable polymeric nanosponges against dual-species bacterial biofilms.
  ACS Biomaterials Science and Engineering
• XIAP knockdown in alcohol-associated liver disease models exhibits divergent in vitro and in vivo phenotypes owing to a potential zonal inhibitory role of SMAC.
  Frontiers in Physiology
• Synovial fluid metal ion levels are superior to blood metal ion levels in predicting an adverse local tissue reaction in failed total hip arthroplasty.
  Journal of Arthroplasty
• In search for biomarkers and potential drug targets for uterine serous endometrial cancer.
  Journal of Cancer Research and Clinical Oncology
• LPCAT1-TERT fusions are uniquely recurrent in epithelioid trophoblastic tumors and positively regulate cell growth.
  PLoS One

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.